Advertisement

Inhibition of 6-Phosphofructo-2-kinase (PFKFB3) Suppresses Glucose Metabolism and the Growth of HER2+ Breast Cancer

Data from a recent clinical trial support the potential clinical utility of PFKFB3 inhibitors as chemotherapeutic agents against HER2+ breast cancer.

 Breast Cancer Research and Treatment